Neuronetics, Inc.
Moat Score — Neuronetics, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Neuronetics holds FDA clearances for the NeuroStar system across multiple depression-related indications and describes itself as the U.S. TMS installed-base leader, giving it real regulatory and brand standing versus smaller rivals like Brainsway and Nexstim, though the clearances themselves are not exclusive. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | The company has no demonstrated low-cost position; in fact, its FY2025 gross margin fell from roughly 72% to about 48.5% after absorbing Greenbrook's lower-margin, labor-intensive clinic operations. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Both the device/session business and the Greenbrook clinics are heavily dependent on third-party insurance reimbursement rates (e.g., TRICARE West coverage decisions), which caps the company's ability to set prices independent of payor policy. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is only a mild network effect, mostly through clinician word-of-mouth and referral patterns among the roughly 5,700 target psychiatric practices; it does not compound the way a true multi-sided platform would. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | A practice that has purchased a NeuroStar system and trained staff on its protocol faces real switching costs to move to a competing TMS device, and a patient mid-course of treatment has practical reasons to finish on the same system, though neither is an extreme lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The U.S. TMS device market is a defensible niche too small to attract the largest medtech players, and Neuronetics' scale as installed-base leader is a real, if modest, barrier against new entrants like CloudTMS. |